The views expressed are those of the authors and not necessarily those of FORCE, the NHS, the National Institute for Health Research, or the Department of Health. “
“Worldwide, gastric cancer is the fourth most common cancer and the second most common cause of cancer deaths [1]. China has a high incidence PD0332991 price of gastric carcinoma. The incidence of gastric cancer
has been increasing in China. In 2008, Chinese cases of gastric cancer accounted for more than 42% of the worldwide incidence [2]. According to the Chinese National Office for Cancer Prevention and Control (Beijing, China), gastric cancer incidence is still the most common cause of cancer death in China, and gastric cancer mortality accounted for nearly one fourth of all cancer deaths [3]. Complete surgical eradication of a gastric tumor represents the best chance for long-term survival. Nevertheless, nearly half of patients will develop recurrence or metastasis in a short period after radical surgery. In the United States, adjuvant chemoradiotherapy is the standard treatment for resectable gastric cancer. In much of Europe, neoadjuvant chemotherapy has become the
preferred treatment strategy. However, the standard of care in Asia is still adjuvant chemotherapy. Many randomized trials have compared adjuvant systemic chemotherapy to surgery alone, with variable results. Some meta-analyses have shown that adjuvant chemotherapy OSI-744 molecular weight has a significant survival benefit [4]. To date, outcomes of adjuvant treatment in gastric cancer remain disappointing. For locally advanced gastric cancer (AGC), the 5-year survival rate reported mafosfamide in the Japanese literature is approximately 50% [5] and is only 8% to 20% in the United States [6]. With the development of new chemotherapy agents, gastric cancer survival has improved. However, the question of which regimen is most effective for gastric cancer
remains unresolved. This study was a single-center prospective phase II trial. In this study, we evaluated the efficacy and safety of docetaxel plus cisplatin and 5-fluorouracil (5-FU) (DCF) regimen as adjuvant chemotherapy for gastric cancer. Eligibility criteria for this study included the following: age of 18 years or older, histologically confirmed gastric or gastroesophageal junction adenocarcinoma, complete resection of the tumor, enrollment between 3 and 6 weeks after radical resection, American Joint Committee on Cancer (AJCC) (version 7.0) stage of IB to IIIC, no prior treatment for gastric cancer, Eastern Cooperative Oncology Group performance status of 0 to 1, and adequate hepatic, renal, and hematologic function [as indicated by serum bilirubin ≤ 1.5 × upper limit of normal (ULN), serum aspartate aminotransferase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine ≤ 1.5 × ULN, hemoglobin ≥ 80 g/l, platelets ≥ 75×109 per liter, and absolute neutrophil count ≥ 1.5×109 per liter]. Patients were ineligible if distant metastases or severe/uncontrolled medical comorbidities were present.